A study shows that early kinetics in DNA methylation and fragment quantity in plasma can predict response to pembrolizumab in patients with advanced solid tumours
Studies investigate the discriminatory capacity of existing prognostic scales and the factors associated with survival to help select patients who may benefit from participation in early phase trials
Addressing cost and affordability issues is now key to increasing the use of this approach in the clinical setting in Asia
Liquid biopsies hold great promise in precision medicine in breast cancer, as shown by the pioneering work of Prof. Nicholas Turner, recipient of the ESMO Award for Translational Research 2023
Tumour agnostic targeted agents and ‘smarter’ dynamic designs are two major areas of interest leading to more patient-centric approaches in cancer care
The 2023 ESMO TAT Honorary Awardee Prof. Susan E. Bates gives an overview of the lasting challenges and unfulfilled potential of these therapies
Despite the promises shown by some innovative technologies in the studies presented, they will not replace existing diagnostic modalities soon
AI technology is being tested across tumour types and with different purposes, with an emerging trend for adding value to whole slide image analyses for HER2 status
A study presented at ESMO Congress 2022 highlights the need to identify predictors of anticancer drug toxicity as more complex treatments become available
However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.